5 completed, 3 terminated, 1 withdrawn. 5 Phase 1, 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Terminated 1, Withdrawn 1 |
| Phase 2 | 4 | Completed 2, Terminated 2 |
| Phase 3 | 1 | Terminated 1 |
Follow KD019: new trials by email Literature Review of KD019 trials Research Report on KD019
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD Tesevatinib, Placebo - Autosomal Dominant Polycystic Kidney, ADPKD | Phase 2 | Completed | Kadmon, a Sanofi Company | 80 | 2017-10-12 | 2023-02-06 |
| A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD) Tesevatinib - Polycystic Kidney, Autosomal Recessive | Phase 1 | Completed | Kadmon Corporation, LLC | 10 | 2017-08-24 | 2022-05-11 |
| Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101 tesevatinib - Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Phase 2 | Terminated | Kadmon Corporation, LLC | 15 | 2015-12-25 | 2022-05-25 |
| KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer KD019 - Esophageal Cancer, Stomach Cancer | Phase 1 | Withdrawn | NYU Langone Health | 2014-12-01 | 2014-08-01 | |
| Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer Tesevatinib, Trastuzumab - HER-2 Positive Breast Cancer, Metastatic Malignant Neoplasm to Brain | Phase 1 / Phase 2 | Terminated | Kadmon Corporation, LLC | 17 | 2014-05-01 | 2022-04-27 |
| KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy KD019, Erlotinib - Carcinoma, Non-Small-Cell Lung | Phase 3 | Terminated | Kadmon Corporation, LLC | 8 | 2011-12-14 | 2022-05-13 |
| Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib XL647 - Carcinoma, Non-Small-Cell Lung | Phase 2 | Completed | Kadmon Corporation, LLC | 41 | 2007-05-01 | 2022-05-13 |
| Study of XL647 Administered Orally Daily to Patients With Solid Tumors XL647 - Cancer | Phase 1 | Completed | Kadmon Corporation, LLC | 31 | 2006-07-01 | 2022-05-13 |
| Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors XL647 - Cancer | Phase 1 | Completed | Kadmon Corporation, LLC | 41 | 2004-06-01 | 2022-05-13 |
Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Polycystic Kidney Diseases (2) · Polycystic Kidney, Autosomal Dominant (2) · Adenocarcinoma (1) · Brain Neoplasms (1) · Esophageal Neoplasms (1) · Neoplasm Metastasis (1) · Polycystic Kidney, Autosomal Recessive (1) · Stomach Neoplasms (1)
Kadmon Corporation, LLC (7) · Kadmon, a Sanofi Company (1) · NYU Langone Health (1)
United States (9)
Harold Keer, M.D., Ph.D. (1) · Jennifer Wu, MD (1)